VivoSeq
Oncology

Myeloproliferative Disorder

41

Pipeline Programs↗

1

Active Trials↗

22

Companies Involved↗

Myeloproliferative Disorder is a moderately active landscape with 41 programs across 22 companies. The most active players are Avyxa, Eli Lilly, Synta Pharmaceuticals Corp.. 5 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

8/100

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1S

Synta Pharmaceuticals Corp.

1 program

Phase 1Sun Pharma logo

Sun Pharma

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 1C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

38 of 41 classified programs — the dominant modality here.

7%ALL OTHERSProtein / enzyme37%

Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed15 · 83%
Terminated1 · 6%
Withdrawn1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Active, not recruiting·Incyte logoIncyte·Phase 1/2·NCT04455841·84 enrolled
A Study in Myeloproliferative Disorders
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01134120·80 enrolled
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Completed·—·Phase 2·NCT00274820·15 enrolled
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Completed·SSynta Pharmaceuticals Corp.·Phase 1·NCT00858572·31 enrolled
Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00002792·20 enrolled
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT00873574·234 enrolled
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Completed·National Cancer Institute (NCI)·Phase 1·NCT00114257·36 enrolled
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
Completed·National Cancer Institute (NCI)·Phase 1·NCT00588991·12 enrolled
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Completed·—·Phase 2·NCT01392989·44 enrolled
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00255346·68 enrolled
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00397813·77 enrolled
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Completed·National Cancer Institute (NCI)·Phase 1·NCT00357305·25 enrolled
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
Completed·MMayo Clinic·Phase 1·NCT00437086·30 enrolled
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Completed·Children's Oncology Group·Phase 3·NCT00003593·254 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00049634·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)